PF-562271

SKU: orb1305448

Description

PF-562271

Research Area

Cardiovascular Research, Cell Biology, Signal Transduction

Key Properties

• CAS Number: 717907-75-0
• MW: 507.49
• Purity: 96.64% (May vary between batches)
• Formula: C₂₁H₂₀F₃N₇O₃S
• SMILES: CN(c1ncccc1CNc1nc(Nc2ccc3NC(=O)Cc3c2)ncc1C(F)(F)F)S(C)(=O)=O
• Target: CDK,FAK,PYK2
• Solubility: Ethanol:< 1 mg/mL (insoluble or slightly soluble);DMSO:235 mg/mL (463.06 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.94 mM)

Bioactivity

• Target IC50:
  PYK2:13 nM|FAK:1.5 nM
• In Vivo:
  PF-562271 binds to the site where ATP and FAK interact, forming inhibitory hydrogen bonds with the main chain atoms in the kinase hinge region. In the chick embryo chorioallantoic membrane, PF-562271 (1 nM) inhibits vascular genesis stimulated by bFGF. In PC3-M cells, PF-562271 (3.3 μM) induces cell cycle arrest at the G1 phase. For A431 cells, PF-562271 (250 nM) inhibits cell invasion into collagen.
  Read more...
• In Vitro:
  In rats implanted with MDA-MB-231 cells in the tibia, oral administration of PF-562271 (5 mg/kg) induced an increase in osteocalcin and trabecular bone, thereby slowing the growth of tumor cells. Oral administration of PF-562271 (25 mg/kg) in mouse models with H125 lung xenograft tumors and PC3M-luc-C6 xenografts inhibited tumor cell growth and induced apoptosis. In mice bearing U87 mg tumors, PF-562271 (oral < 33 mg/kg) was able to inhibit tumor FAK phosphorylation in a time- and dose-dependent manner. Oral administration of PF-562271 (50 mg/kg) in BxPc3 and PC3-M xenograft mice effectively inhibited tumor growth.
  Read more...
• Cell Research:
  PF-562271 (Haoyuan Chemexpress Co., Ltd.) is dissolved in DMSO and stored, and then diluted with appropriate media before use. Ewing sarcoma cells are plated in 10-cm dishes, allowed to adhere for 24 hours, and then treated with PF-562271, PD0325901, or Dasatinib. ATP content is measured as a surrogate for cell number using the CellTiter-Glo Luminescent Cell Viability Assay. Luminescence readings are obtained using the FLUOstar Omega microplate reader. For experiments with small-molecule treatment, 1.25×103 Ewing sarcoma cells are seeded in each well and treated with a range of concentrations. IC50 values are calculated from ATP measurements obtained after 3 days of treatment using log-transformed, normalized data in GraphPad Prism 5.0. Cell lines are also treated with compound in 6-cm dishes, trypsinized, and counted by light microscopy using trypan blue exclusion. For experiments using shRNA-transduced cells, 1.25×103 cells are seeded per well into 384-well plates on day 3 posttransduction. ATP content is measured on days 3, 6, and 8 posttransduction.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

inhibit, Focal adhesion kinase, FAK, Ewing, Inhibitor, CDK3/CyclinE, CDK2/CyclinE, CDK1/CyclinB, Breast, Antitumor, Cancer, PF562271, PF-562271, PF 562271, PYK2, Pyk2, Sarcoma, PTK2, PTK2 protein tyrosine kinase 2, Proline-rich tyrosine kinase 2, VS6062, VS-6062, VS 6062

Compound Identifiers

PubChem CID

11713159